Effect of glimepiride on the pharmacokinetics of teneligliptin in healthy Korean subjects
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Jin-Woo | - |
dc.contributor.author | Kim, Kyoung-Ah | - |
dc.contributor.author | Choi, Yun Jung | - |
dc.contributor.author | Yoon, Soo Hyun | - |
dc.contributor.author | Park, Ji-Young | - |
dc.date.accessioned | 2021-09-01T05:07:16Z | - |
dc.date.available | 2021-09-01T05:07:16Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2019-10 | - |
dc.identifier.issn | 0269-4727 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/62744 | - |
dc.description.abstract | What is known and objective Teneligliptin is a DPP-4 inhibitor used for the treatment of type 2 diabetes mellitus, commonly prescribed in combination with glimepiride. Teneligliptin is metabolized by CYP3A4, and glimepiride might be partly metabolized by CYP3A4. The aim of the study was to investigate the possible effect of glimepiride on the pharmacokinetics of teneligliptin in healthy subjects. Methods A repeated dose, open-label, fixed-sequence study was conducted in 26 healthy subjects. All participants were administered 20 mg teneligliptin daily for 6 days. On day 7, 4 mg glimepiride was administered together with 20 mg teneligliptin. Plasma teneligliptin concentrations were measured at a steady state, and its pharmacokinetic characteristics were compared without and with glimepiride. Results and discussion No statistically significant difference was found in the effect of glimepiride on teneligliptin pharmacokinetics. The steady-state C-max,C-ss values of teneligliptin without and with glimepiride were 207.01 ng/mL and 202.15 ng/mL, respectively. Its AUC(tau) values at steady-state without and with glimepiride were 1527.8 ng center dot h/mL and 1578.6 ng center dot h/mL, respectively. The point estimation of geometric mean ratios (GMR) and the 90% confidence interval for both C-max,C-ss and AUC(tau) were within the equivalence range of 0.8-1.25. The results of the present study revealed that glimepiride did not cause pharmacokinetic interaction with teneligliptin in humans. What is new and conclusion Glimepiride did not affect the pharmacokinetic characteristics of teneligliptin in healthy subjects. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | TYPE-2 DIABETES-MELLITUS | - |
dc.subject | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | - |
dc.subject | CYTOCHROME-P450 ENZYMES | - |
dc.subject | SULFONYLUREA TREATMENT | - |
dc.subject | DRUG-INTERACTIONS | - |
dc.subject | SAFETY | - |
dc.subject | PHARMACODYNAMICS | - |
dc.subject | POLYMORPHISMS | - |
dc.subject | KETOCONAZOLE | - |
dc.subject | GLYBURIDE | - |
dc.title | Effect of glimepiride on the pharmacokinetics of teneligliptin in healthy Korean subjects | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Ji-Young | - |
dc.identifier.doi | 10.1111/jcpt.12848 | - |
dc.identifier.scopusid | 2-s2.0-85066030225 | - |
dc.identifier.wosid | 000485291100008 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, v.44, no.5, pp.720 - 725 | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS | - |
dc.citation.title | JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS | - |
dc.citation.volume | 44 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 720 | - |
dc.citation.endPage | 725 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | TYPE-2 DIABETES-MELLITUS | - |
dc.subject.keywordPlus | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | - |
dc.subject.keywordPlus | CYTOCHROME-P450 ENZYMES | - |
dc.subject.keywordPlus | SULFONYLUREA TREATMENT | - |
dc.subject.keywordPlus | DRUG-INTERACTIONS | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | PHARMACODYNAMICS | - |
dc.subject.keywordPlus | POLYMORPHISMS | - |
dc.subject.keywordPlus | KETOCONAZOLE | - |
dc.subject.keywordPlus | GLYBURIDE | - |
dc.subject.keywordAuthor | drug interaction | - |
dc.subject.keywordAuthor | glimepiride | - |
dc.subject.keywordAuthor | pharmacokinetics | - |
dc.subject.keywordAuthor | teneligliptin | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.